RE: AVACTA - my view19 Apr 2023 08:54
This notion of full or fair value is never going to happen. Otherwise there is no point in buying the company. The buyer will want to get a low price to then profit from the company assets later.
I know I keep banging on about this, but its money we are talking about, not the science.
Right now as best as I can see, we have the 2 strands working to expectation (which was pretty high from the outset).
What we don't know is when the trials will be finished and at quite what level of efficacy they will have.
So until that is known, you can't see yet the actual applications rather than just the very broad , general areas us lot think COULD be addressed by the tech.
So when will it be available, what cancers will it be used on first, how will it be administered, ie lots more dox doses or big ger injections, and how much profit will be made?
We are I think still timewise many months, maybe a couple of years away from this info.
In the meantime I would expect the SP to drift up as more good news is released but right now, I think the market is probably nervous on cash burn and cash on hand and how well LD is doing to help keep the money coming in. So given none of us have a clue where we are on the basic financials I imagine the market is the same, therefore I would not be surprised to see a dip in the SP as this nervousness is translated to a bit of selling to the run up next week.
If the TU is as expected (ie cash flow under control, at least a slight increase t in LD's turnover and profit), then I would expect to see quite a jump as nerves would be calmed.
So who knows where this is going in the short term, but as we have all seen the short term soon becomes the long term and I for one never imagined that with the tech performing this well, this long into the trial, that we would be hanging on to 130p a share.